BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16152608)

  • 1. Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population.
    Hu Z; Ma H; Lu D; Qian J; Zhou J; Chen Y; Xu L; Wang X; Wei Q; Shen H
    Int J Cancer; 2006 Mar; 118(5):1275-8. PubMed ID: 16152608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population.
    Ma H; Hu Z; Zhai X; Wang S; Wang X; Qin J; Jin G; Liu J; Wang X; Wei Q; Shen H
    Cancer Lett; 2006 Aug; 240(2):261-7. PubMed ID: 16288830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDM2 SNP309 polymorphism is associated with colorectal cancer risk.
    Wang W; Du M; Gu D; Zhu L; Chu H; Tong N; Zhang Z; Xu Z; Wang M
    Sci Rep; 2014 May; 4():4851. PubMed ID: 24797837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDM2 promoter polymorphism and p53 codon 72 polymorphism in chronic myeloid leukemia: the association between MDM2 promoter genotype and disease susceptibility, age of onset, and blast-free survival in chronic phase patients receiving imatinib.
    Liu YC; Hsiao HH; Yang WC; Liu TC; Chang CS; Yang MY; Lin PM; Hsu JF; Lee CP; Lin SF
    Mol Carcinog; 2014 Dec; 53(12):951-9. PubMed ID: 23818300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate.
    Gansmo LB; Vatten L; Romundstad P; Hveem K; Ryan BM; Harris CC; Knappskog S; Lønning PE
    Oncotarget; 2016 May; 7(19):28637-46. PubMed ID: 27081698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of p53 R72P polymorphism in the association of MDM2-SNP309 with breast cancer.
    Leu JD; Wang CY; Tsai HY; Lin IF; Chen RC; Lee YJ
    Oncol Rep; 2011 Jun; 25(6):1755-63. PubMed ID: 21479369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P53 Arg72Pro and MDM2 SNP309 polymorphisms cooperate to increase lung adenocarcinoma risk in Chinese female non-smokers: a case control study.
    Ren YW; Yin ZH; Wan Y; Guan P; Wu W; Li XL; Zhou BS
    Asian Pac J Cancer Prev; 2013; 14(9):5415-20. PubMed ID: 24175836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of Helicobacter pylori with genetic variants in the MDM2 promoter, is associated with gastric cancer susceptibility in Chinese patients.
    Wang X; Yang J; Ho B; Yang Y; Huang Z; Zhang Z; Zhang G
    Helicobacter; 2009 Oct; 14(5):114-9. PubMed ID: 19751436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
    Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
    Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis.
    Li G; Zhai X; Zhang Z; Chamberlain RM; Spitz MR; Wei Q
    Carcinogenesis; 2006 Oct; 27(10):2028-33. PubMed ID: 16675470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDM2 promoter SNP309 is associated with risk of occurrence and advanced lymph node metastasis of nasopharyngeal carcinoma in Chinese population.
    Zhou G; Zhai Y; Cui Y; Zhang X; Dong X; Yang H; He Y; Yao K; Zhang H; Zhi L; Yuan X; Qiu W; Zhang X; Shen Y; Qiang B; He F
    Clin Cancer Res; 2007 May; 13(9):2627-33. PubMed ID: 17473193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Genetic polymorphism in MDM2 is associated with susceptibility to colorectal cancer in a Chinese population].
    Liu JN; Zhang XM; Guo YL; Sun T; Lin DX; Wen T
    Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):335-8. PubMed ID: 18953830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore.
    Chua HW; Ng D; Choo S; Lum SS; Li H; Soh LY; Sabapathy K; Seow A
    BMC Cancer; 2010 Mar; 10():88. PubMed ID: 20219101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon.
    Gansmo LB; Knappskog S; Romundstad P; Hveem K; Vatten L; Lønning PE
    Int J Cancer; 2015 Jul; 137(1):96-103. PubMed ID: 25431177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
    Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
    Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population.
    Akkiz H; Sümbül AT; Bayram S; Bekar A; Akgöllü E
    Cancer Epidemiol; 2010 Aug; 34(4):448-52. PubMed ID: 20447891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis.
    Wan Y; Wu W; Yin Z; Guan P; Zhou B
    BMC Cancer; 2011 May; 11():208. PubMed ID: 21619694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic variations in MDM2 and P53 genes confer risk for adult acute lymphoblastic leukemia in a Chinese population.
    Chen J; Zhu B; Chen J; Li Y
    DNA Cell Biol; 2013 Jul; 32(7):414-9. PubMed ID: 23745682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between polymorphisms of TP53 and MDM2 and prostate cancer risk in southern Chinese.
    Xu B; Xu Z; Cheng G; Min ZC; Mi Y; Zhang ZZ; Tao J; Li PC; Wang ML; Tang JL; Zhang ZD; Zhang W; Wu HF; Feng NH; Hua LX
    Cancer Genet Cytogenet; 2010 Oct; 202(2):76-81. PubMed ID: 20875869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer.
    Zhang X; Miao X; Guo Y; Tan W; Zhou Y; Sun T; Wang Y; Lin D
    Hum Mutat; 2006 Jan; 27(1):110-7. PubMed ID: 16287156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.